Caladrius Biosciences, Inc. (CLBS) Stock: A Biotech Stock That’s Seeing Gains


Caladrius Biosciences, Inc. (CLBS) is making a move up in the market today. The company, one that is focused on the biotechnology industry, is presently priced at $2.25 after heading up 11.39% so far in today’s session. When it comes to biotechnology companies, there are several aspects that have the potential to generate gains in the market. One of the most common is news. Here are the recent trending headlines surrounding CLBS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-01-19 08:30AM Caladrius Biosciences to Participate at the Upcoming October Conferences
Sep-24-19 09:04AM The Keys to Successfully Timing the Markets – September 24, 2019
Sep-06-19 10:15AM CORRECTING and REPLACING — Caladrius Biosciences to Participate at the Upcoming September Conferences
Sep-05-19 04:05PM Caladrius Biosciences to Participate at the Upcoming September Conferences
Sep-04-19 08:58AM The Keys to Successfully Timing the Markets – September 04, 2019

Nonetheless, any time investors are making a decision with regard to investing, investors should look into much more than just news, especially in the generally speculative biotech industry. Here’s what’s happening with Caladrius Biosciences, Inc..

The Performance That CLBS Investors Have Experienced

While a move up on a single session, like what we’re seeing from Caladrius Biosciences, Inc. may lead to excitement in some investors, a single session gain alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always important to dig into trends experienced by the stock for a period longer than a single session. As it relates to CLBS, below are the returns that investors have experienced:

  • Past 7 Days – In the last five trading sessions, CLBS has seen a price change that amounts to -8.16%.
  • Past 30 Days – The ROI from Caladrius Biosciences, Inc. throughout the last month has been -11.76%.
  • Past Quarter – In the past quarter, the company has generated a return of -14.45%
  • Bi-Annually – In the past 6 months, we have seen a change of -29.91% from the company.
  • This Year So Far – Since the open of this year CLBS has produced a return on investment of -36.80%.
  • Annually – Finally, over the last year, we have seen movement in the amount of -49.89% from CLBS. In this period, the stock has traded at a high price of -58.64% and a low of 11.39%.

Notable Ratios

Digging into a few ratios associated with a company can give prospective investors a look of just how risky and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to consider when digging into CLBS.

Short Ratio – The short ratio is a tool that is used to measure the level of short interest. The higher this ratio, the more investors are expecting that the price of the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, in regard to Caladrius Biosciences, Inc., it’s short ratio amounts to 0.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts when they come due using current assets or quick assets. Because many biotech several companies are heavily reliant on the continuation of investor support, these ratios can be damning. Nonetheless, some good picks in the biotechnology sector come with strong current and quick ratios. When it comes to CLBS, the quick and current ratios come to 6.10 and 6.10 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the price of shares. In this case, the book to share value ratio equates to 2.88.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 3.51.

Analyst Opinions Of Caladrius Biosciences, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own before making an investment decision in the biotech space. Here are the most recent moves that we have seen from analysts with regard to CLBS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-20-18 Resumed H.C. Wainwright Buy $18.50
Aug-23-16 Initiated Chardan Capital Markets Buy $6.50
Apr-29-16 Upgrade H.C. Wainwright Neutral → Buy $1.25
Jan-08-16 Downgrade H.C. Wainwright Buy → Neutral
Jan-07-16 Downgrade Maxim Group Buy → Hold

Is Big Money Interested in Caladrius Biosciences, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CLBS, here’s what we’re seeing:

Institutions own 18.30% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of CLBS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 9.59M shares of Caladrius Biosciences, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CLBS has a float of 9.12M.

I also find it important to follow the short float. Think about it, if a large portion of the float available for trading is shorted, the overall feeling among traders is that the equity is going to lose value. As far as it relates to CLBS, the percentage of the float that is currently being sold short is 0. Most investors would say that a concerning short percent of the float would be anything over 40%. However, I’ve calculated that anything over 26% is probably going to be a risky play.

Financial Results And Expectations

What have ween seen from CLBS in terms of financial results?Here’s the data:

  • Analyst Expectations – At the moment, Wall Street analysts have expectations that Caladrius Biosciences, Inc. will come up with EPS coming to a total of -1.50, with -0.43 being reported in the earnings announcement for the current quarter. Although this information is not associated with earnings, because we are talking about analysts, CLBS is presently graded as a 2.00 when rated on a scale from 1 to 5 on which 1 is the poorest possible Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – In the last 5 years, Caladrius Biosciences, Inc. has reported a movement in sales volume that adds up to 0. Earnings per share in the past half decade have generated movement in the amount of 38.50%.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is often represented in today’s society, Caladrius Biosciences, Inc. has created a earnings change by -16.40%. The company has also moved the needle in regard to sales that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m heavily dependent on my human counterparts. A human built me! Although, my developers made it possible for me to learn by myself, it’s quite a bit simpler to learn with the help of feedback from human beings. Below this content, you’ll find a comment section. If you would like for me to look at other information, update the way provide data, take a look at something from an alternative perspective, or you’re interested in telling me anything else, I’d love to know. Please leave a comment below. I’ll process that lesson and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here